AstraZeneca PLC ("AstraZeneca", "the Company") will today host a conference call
for investors and analysts. This will focus on key potential medicines within
the late-stage pipeline and will provide further details on the progress made in
2015 and the anticipated news flow in 2016. No material new information will be
included; the call is intended to offer additional insight on the pipeline.
The event will be led by Sean Bohen, Executive Vice President, Global Medicines
Development and Chief Medical Officer, alongside AstraZeneca experts from each
of the Company's main therapy areas and will take place at 16:00 - 17:30 GMT
(11:00 - 12:30 EST).
The dial-in details for the conference call are as follows:
UK 0800 694 2370
US 866 977 7645
International +44 1452 557749
Sweden 0200 883 079
Code 79258160
The accompanying presentation will be available for download at
astrazeneca.com/investors (http://www.astrazeneca.com/investors/) one hour prior
to the start of the call. A link to the live audio webcast will also be
available at this address. An indexed version and transcript of the webcast will
be published in due course.
A replay of the call can be accessed from 17:30 GMT today via the following
numbers:
UK 0800 953 1533
US 866 247 4222
International +44 1452 550000
Code 79258160
Reporting Calendar
The Company intends to publish its full-year financial results on 4 February
2016.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy areas -
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology - as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information,
please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Esra Erkal-Paler UK/Global +44 20 7604 8030
Vanessa Rhodes UK/Global +44 20 7604 8037
Karen Birmingham UK/Global +44 20 7604 8120
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen Oncology +44 7818 524185
Eugenia Litz RIA +44 7884 735627
Nick Stone CVMD +44 7717 618834
Craig Marks Finance +44 7881 615764
Christer Gruvris Consensus Forecasts +44 7827 836825
US
Lindsey Trickett Oncology, ING +1 240 543 7970
Mitchell Chan Oncology +1 240 477 3771
Toll-Free +1 866 381 7277
Key: RIA - Respiratory, Inflammation & Autoimmunity, CVMD - Cardiovascular &
Metabolic Disease,
ING - Infection, Neuroscience & Gastrointestinal
02 December 2015
-ENDS-
ASTRAZENECA PLC ANNOUNCES LATE-STAGE PIPELINE CONFERENCE CALL FOR INVESTORS AND ANALYSTS
| Source: AstraZeneca PLC
Attachments
